12].

Treatment regimens vary and are a matter for clinical judgment, with typical activities in the range 150–250   MBq. The EANM Guideline suggests two regimens in current use, based on using either an activity per surface area or a fixed starting activity which is incremented. The use of ³²P to treat PRV was first reported in 1955 [13], but Parmentier [12], in a review in 2005 stated: ‘Few data are available regarding precise dosimetry in man’. An effective dose (ED) of 2.4   mSv/MBq is given by the International Commission for Radiation Protection (ICRP) in ICRP80 [14], with 11   mGy/MBq for both the bone surfaces and red marrow in ICRP53 [15]. Values of the same order of magnitude may be found in the literature.

Related posts:

descriptors of the radionuclide imaging process Radiotherapy beam production photon therapy trends Dentition

Stay updated, free articles. Join our Telegram channel

Join